Summary
Johnson & Johnson (JNJ) filed an 8-K/A amendment on April 16, 2024, primarily to provide an updated exhibit. This filing includes a press release dated April 16, 2024, which likely contains financial results for the period ended March 31, 2024. Investors should refer to this press release for the latest updates on the company's performance, including key financial metrics, segment results, and any forward-looking guidance that may have been provided. The nature of this filing as an amendment suggests that the original 8-K filing may have been incomplete or that additional information, specifically the press release, was required. Investors should carefully review the press release for details regarding JNJ's first-quarter 2024 performance, as this is the primary informational content being added via this amendment.
Key Highlights
- 1Johnson & Johnson (JNJ) filed an 8-K/A amendment on April 16, 2024.
- 2The amendment's primary purpose is to include Exhibit 99.1, a Press Release dated April 16, 2024.
- 3The press release likely contains financial results for the period ended March 31, 2024.
- 4This filing supplements a previous 8-K report.
- 5Investors should consult the press release for detailed financial performance updates for the quarter ending March 31, 2024.
- 6The filing also includes the cover page in Inline XBRL format.